SCHEMBL30774813

SCHEMBL30774813

CN(Cc1nnnn1-c1ccc(Br)c(C#N)c1)C1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS2 P35228 11/20 0.40
▸ NOS3 P29474 10/20 0.40
▸ NOS1 P29475 10/20 0.40
▸ ABCB11 O95342 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.36
▸ AR P10275 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ SLC6A2 P23975 1/20 0.36
▸ PDE4A P27815 1/20 0.36
▸ SLC6A4 P31645 1/20 0.36
▸ SLC6A3 Q01959 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ SIGMAR1 Q99720 1/20 0.36
▸ HTT P42858 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ POLB P06746 2/20 0.34
▸ KMT2A Q03164 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30774828 0.89 NOS2 (0.36) NOS2NOS3NOS1HTTALDH1A1
SCHEMBL30774788 0.88 ALDH1A1 (0.43) NOS2NOS3NOS1HTTALDH1A1
SCHEMBL30774893 0.88 NOS2 (0.38) NOS2NOS3NOS1HTTALDH1A1
SCHEMBL30774803 0.86 PRMT1 (0.36) NOS2NOS3NOS1ARHTT
SCHEMBL30774815 0.86 ALDH1A1 (0.42) NOS2NOS3NOS1ARLMNA
SCHEMBL31448690 0.81 ALDH1A1 (0.44) NOS2NOS3NOS1CYP2D6HTT
SCHEMBL30774810 0.81 ALDH1A1 (0.44) NOS2NOS3NOS1CYP2D6HTT
SCHEMBL30774771 0.80 ALDH1A1 (0.35) NOS2NOS3NOS1SLC6A4ALDH1A1
SCHEMBL30774819 0.80 ALDH1A1 (0.41) ABCB11ADORA3ARCYP2D6SLC6A2
SCHEMBL30774865 0.79 PRMT1 (0.36) LMNAALDH1A1MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049068-A1 Substituted Tetrazolyl Compounds Useful as T Cell Activators BRISTOL MYERS SQUIBB CO (US) 2026-02-19 — — US claimed
CN-119654312-A Substituted tetrazolyl compounds useful as T cell activators 百时美施贵宝公司 2025-03-18 — — CN claimed
US-20260049068-A1 Substituted Tetrazolyl Compounds Useful as T Cell Activators BRISTOL MYERS SQUIBB CO (US) 2026-02-19 — — US disclosed
EP-4568950-A1 SUBSTITUTED TETRAZOLYL COMPOUNDS USEFUL AS T CELL ACTIVATORS Bristol-Myers Squibb Company (US) 2025-06-18 — — EP disclosed
CN-119654312-A Substituted tetrazolyl compounds useful as T cell activators 百时美施贵宝公司 2025-03-18 — — CN disclosed
WO-2024036100-A1 SUBSTITUTED TETRAZOLYL COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2024-02-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049068-A1 Substituted Tetrazolyl Compounds Useful as T Cell Activators DGKZ, DGKA, DGKG NOS2 3835/4885NOS3 3443/4885NOS1 3288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback